Combination Treatment of Timosaponin BII and Pirfenidone Attenuated Pulmonary Fibrosis Through Anti-Inflammatory and Anti-Fibrotic Process in Rodent Pulmonary Fibrosis Model and Cellular Epithelial–Mesenchymal Transition Model
Molecules · 18.04.2025 · 30 (8) · 1821
DOI: 10.3390/molecules30081821 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 18.04.2025. Verfasst von Xuebin Shen und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Wannan Medical College, Wuhu 241002, China. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Saponins, Pulmonary Fibrosis, Pyridones. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of the Higher Education Institutions of Anhui Province, Research Funds of Center for Xin'an Medicine and Modernization of Traditional Chinese Medicine of IHM, Research Funds of Center for Xin’an Medicine and Modernization of Traditional Chinese Medicine of IHM.
Abstract (Originalsprache)
Pulmonary fibrosis (PF) is a progressive lung disease with a poor prognosis. Pirfenidone (PFD) can slow down the decline of lung function, but defects in efficacy and accompanying side effects limit its application; hence, implementing methods including combination therapy might be a viable option. Given this, we hypothesized that combining timosaponin BII (TS BII) with PFD might offer a more effective treatment approach. Bleomycin-induced rodent PF model and TGF-β1-induced cellular epithelial–mesenchymal transition (EMT) model were applied in the study. The results showed that the combination of TS BII and PFD was more effective in reducing the production of IL-1β, TNF-α, collagen fibers, hydroxyproline, and MDA. Moreover, the combination treatment could better restore levels SOD and GSH-Px. In addition, TS BII combined with PFD could downregulate the expression of NF-κB and the ratio of p-IκBα/IκBα, and modulate the aberrant expression of epithelial–mesenchymal transition markers. In addition, the combination treatment could regulate the intestinal flora of PF mice. It is worth noting that among the above results, there were significant differences (p < 0.05) between the combination group and either the TS BII or PFD monotherapy group. These findings indicate that the combination of TS BII and PFD has a synergistic effect in the treatment of PF and represents a promising treatment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Wannan Medical College, Wuhu 241002, China.
- School of Pharmacy, Anhui College of Traditional Chinese Medicine, Wuhu 241003, China.
- School of Biological and Food Engineering, Engineering Research Center for Development and High Value Utilization of Genuine Medicinal Materials in North Anhui Province, Suzhou University, Suzhou 234000, China.
- Center for Xin'an Medicine and Modernization of Traditional Chinese Medicine of IHM, Hefei 230051, China.
ORCID-Profile: Xuebin Shen, Kefeng Zhai, Sihui Nian, Limin Liu
Förderung
- Natural Science Foundation of the Higher Education Institutions of Anhui Province
- Research Funds of Center for Xin'an Medicine and Modernization of Traditional Chinese Medicine of IHM
- Research Funds of Center for Xin’an Medicine and Modernization of Traditional Chinese Medicine of IHM
- Municipal Science and Technology Project of Wuhu Science and Technology Bureau
- Key Science and Technology Program of Anhui Province
- The University Synergy Innovation Program of Anhui Province
- Key Science and Technology Program of Wuhu City
- Key Natural Science Research Project of Anhui Provincial Department of Education
Zitieren
APA
Shen, X., Zheng, Y., Yang, H., Liu, L., Yu, L., Zhang, Y., Song, X., He, Y., Jin, R., Jiao, J., Gu, Z., Zhai, K., Nian, S., & Liu, L. (2025). Combination Treatment of Timosaponin BII and Pirfenidone Attenuated Pulmonary Fibrosis Through Anti-Inflammatory and Anti-Fibrotic Process in Rodent Pulmonary Fibrosis Model and Cellular Epithelial–Mesenchymal Transition Model. Molecules, 30(8), 1821. https://doi.org/10.3390/molecules30081821
Vancouver
Shen X, Zheng Y, Yang H, Liu L, Yu L, Zhang Y, et al. Combination Treatment of Timosaponin BII and Pirfenidone Attenuated Pulmonary Fibrosis Through Anti-Inflammatory and Anti-Fibrotic Process in Rodent Pulmonary Fibrosis Model and Cellular Epithelial–Mesenchymal Transition Model. Molecules. 2025;30(8):1821. doi:10.3390/molecules30081821
BibTeX
@article{Shen2025,
author = {Shen, Xuebin and Zheng, Yueyue and Yang, Hui and Liu, Li and Yu, Lizhen and Zhang, Yuanxiang and Song, Xiaojun and He, Yuqing and Jin, Runze and Jiao, Jianhao and Gu, Zhihui and Zhai, Kefeng and Nian, Sihui and Liu, Limin},
title = {Combination Treatment of Timosaponin BII and Pirfenidone Attenuated Pulmonary Fibrosis Through Anti-Inflammatory and Anti-Fibrotic Process in Rodent Pulmonary Fibrosis Model and Cellular Epithelial–Mesenchymal Transition Model},
journal = {Molecules},
year = {2025},
volume = {30},
number = {8},
pages = {1821},
doi = {10.3390/molecules30081821}
}
EUVIMED